Jon Napitupulu

PacBio reported fourth-quarter 2025 revenue of $44.6 million, up 14% year over year and 16% sequentially, bringing full-year revenue...

Grace Therapeutics has a PDUFA date of April 23, 2026 for GTX-104, its intravenous formulation of nimodipine for aneurysmal...

Ocular Therapeutix will unveil topline results from SOL-1, its Phase 3 superiority trial of AXPAXLI (OTX-TKI) in wet age-related...

Neuronetics reported preliminary, unaudited fourth-quarter and full-year 2025 results showing material step-up in scale following its integration of Greenbrook...

PacBio reported fourth-quarter 2025 revenue of $44.6 million, up 14% year over year and 16% sequentially, with full-year revenue...

Orchestra BioMed granted stock options covering 120,000 shares to nine new hires under its Nasdaq-compliant inducement plan, signaling a...

Ocular Therapeutix will unveil topline results from SOL-1, its phase 3 superiority trial of AXPAXLI (OTX-TKI) in wet age-related...

CorMedix Therapeutics will spend mid‑March on the investor circuit, hosting fireside chats at Leerink Partners and Citizens Life Sciences...

Orion reported a step-change 2025, with net sales up 22.5% to €1.89 billion and operating profit up 51.6% to...

Ipsen reported 2025 sales of €3.68 billion, up 10.9% at constant exchange rates, with core operating income rising 16.7%...